
    
      The purpose of this study is to further describe the safety and tolerability of ORALAIR
      tablets in children 5 to 9 years of age with grass-pollen-induced allergic rhinitis with or
      without conjunctivitis.

      Patients are followed for safety and tolerability during the first 30 treatment days.
    
  